VF
VRPX

Virtu Financial’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Virtu Financial’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-946
Closed -$9K – 2237
2024
Q4 		$9K Buy
+946
New +$12.6K ﹤0.01% 1400
2022
Q1 		– Sell
-61
Closed -$52K – 2233
2021
Q4 		$52K Buy
61
+6
+11% +$6.18K 0.01% 1334
2021
Q3 		$66K Sell
55
-40
-42% -$83.8K 0.01% 1228
2021
Q2 		$107K Buy
+95
New +$102K 0.01% 1188

Other funds holding VRPX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return

Virtu Financial's VRPX Position: Q1 2025 in Review

Virtu Financial sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2025, closing a stake of 946 shares — an estimated $9K sold.

Virtu Financial first reported a position in VRPX in Q2 2021 and held it in 4 quarters. The position peaked at $107K in Q2 2021. 7 funds tracked by Wall St. Rank hold VRPX as of Q1 2025.

  • Virtu Financial reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 946 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $9K.
  • Virtu Financial first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Virtu Financial's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $107K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.